the vaccine is called mrna-1273 and sean is one of 45 people in atlanta and seattle that are part ofhase in the study. testing it for safety. >> i think to myself, if you were my son and you came to me and said i want to do this, what would i tell you? did you ever have a conversation like that with your parents or anybody else? >> yes. there were conversations that i had with friends and family. but they trusted my judgment. >> so here's how it works. >> i gave some blood samples to be used as a baseline for assessing my health after getting the vaccine. and to, also, use a baseline to determine whether or not there was any sort of immune response my body was able to generate in response to the vaccine later. >> if it's successful, it may not only help get the world back to normal but it could also be a game changer for other therapeutics and vaccines. why? because of its technology. instead of using the actual virus, which could inadvertently cause an infection or even an inactivated form of the virus, this vaccine relies on mrna. emergen messenger rna, which is just a genetic blue

the vaccine is called mrna-1273.ean is one of 45 people in atlanta and seattle part of the first phase of the study. testing it for safety. >> i think to myself, if you were my son and came to me and said i want to do this, what would i tell you? did you have a conversation like that with your parents or anybody else? >> yes, there were conversations i had with friends and family, but they trusted my judgment. >> reporter: so here's how it works -- >> i gave some blood samples to be used as a baseline for assessing my health after getting the vaccine and to also use as baseline to determine whether or not there was any sort of immune response my body was able to generate in response to getting the vaccine later. >> if it's successful, it may not only help to get the world back to normal, but it could be a game changer for other theory p -- their pew you cans and vaccines. instead of using the virus, which could form an infection, this vaccine relies on messenger rna, which is a genetic blueprint of the virus. it dire

there are — there is an approach called mrna vaccine that people like moderna, curevac and several otherswe can't count on that, so we'll back, you know, four or five of those and four orfive companies using a more conventional approach, which unfortunately, the schedule for that probably wouldn't be as quick as this rna programme we've been funding directly and through cepi over the last decade. you'll be aware a lot of people in the uk are asking what is a very simple and straightforward question, which is, when will there be a vaccine? what — how do you see that? well, it's a perfect question, because we want to get back to the life we had before coronavirus. and people are seeing the economic destruction, the psychological stress. you know, this is such an unprecedented, very tough thing to deal with. the — people like myself and tony fauci are saying 18 months. if everything went perfectly, we could do slightly better than that, but there will be a trade—off — we'll have less safety testing than we typically would have, and so, governments will have to decide do they indemnify the co

they are using a brand-new technology called mrna which is essentially like if you think of a computerou want to download antivirus software, madera technology is giving technologies to a human on how to combat a virus, so if this works for coronavirus, it makes the case for other mrna technology across the board. his company has another clinical trial that is ongoing and they are expected to have data come out in q3. there is a lot of new innovation the news of the coronavirus is overshadowing. haidi: how do you pick the names you like in that space? it is very crowded. nina: it is definitely crowded. what we do is fundamental we use a and proprietary group of segmentation. innovatione happening over the next five to 10 years in health care? robotics, precision medicine to enomics, this is where disruption is happening. of all the companies in those various areas, we have looked at the technology leaders and the market leaders across the board and we basically picked the number one or the number two from all of these spaces, and through this fundamental research, we compiled a list of

or drugs based on mrna.s a brand-new virus and you're moving at lightning speed for the trials for covid-19. tell us, you're thinking about having a vaccine ready for high risk groups like health care workers in the fall. how much data, how long do you need to be able to make sure that this is really safe and in how many people? how long does that take to be able to figure out >> yes, that's a great question. that's a dialogue we have with regulators planning the rate of phase one we have phase one. the phase one study in early summer, we pick up the dose as early as late summer, early fall what i'm trying to do is get as much as we can to understand the safety and the study we're going to do some additional studies outside the u.s. just to be able to understand the safety. >> stephane, what is the next thing that we should be watching how quickly do you think a vaccine can be developed that would be mass produced i think that's the big question when we start to wonder when we can re-open society based on co

. >> we also have another shot which is an mrna which is a cutting edge technology. we are bringing both forward. two shots on goal. we are delighted to be bringing them forward and trying to do something to help patients. >> the can fadian in me loves t statement two shots on goal. and joining me now is the infectious disease physician with the special pathogens unit and our msnbc contributor. pa matthew, let's start with you. tell me about the report you wrote about the study. it was detailed and in depth, but for our viewers who are desperate for a solution or treatment for coronavirus, tell me what the study is about. >> i want to emphasize this is a reason for hope. this is a suggestion. it is not a definitive in terms of the results of the study. this is one center from the first clinical trial of remdesivir. one of the first drugs pu s put testing against covid-19. what we obtained is a video that was sent to faculty at university of chicago where one of the investigators from the trial -- there are dozens of hospitals involved in the trial -- this is just one

we are thinking about new technologies and vaccine development, particularly with mrna that could potentially lead to a much faster access to a vaccine. so with so many people pursuing this, i think we have to be optimistic. but realistically it may take a longer time than that. so we have to prepare for a world without a vaccine where coronavirus is going to be present in the community. >> irwin, who it affects really does different. it mimics the idea that in poor, highly concentrated areas you're seeing it. in singapore, they saw resurgence in some of the migrant communities where people live in tight quarters. here in the united states you have the navajo nation and other native communities where there isn't water to wash your hands at home. >> we have a real problem with distar disparities in access to health care in general. it happens on a global nature as well as here in the u.s. it's extremely concerning what's happening in the navajo nation and we're about to see surges in many, many under servserved communities. even in new york city, the epicenter, there are serious disparities in

i'm asking about whether mrna is going to be a good vaccine candidate or not and we're talking about, that is not, you know, i guess maybe we should stop talking about it as well because it's not -- it's of no use to the american public. >> yeah, well, by the way, this is of course the president. tomorrow he's going to talk more about it because he's going to try to, you know, spend the night stewing about it, formulate some new lie and then go after it tomorrow. secretary sebelius, i mean, in a normal time shouldn't scientists be able to speak directly to the american people not filtered through the lens of, you know, the white house or the vice president's office? i mean, shouldn't there be cdc briefings and hhs briefings and, you know, directly scientific information and questions being asked and answered? >> it would be really helpful if we would have anthony fauci, dr. debbie birx, both of whom are excellent and have incredible reputations. and then a, you know, whether it's dr. redfield or somebody from the cdc should be by their side every day. they're the epidemiologists. tha

year, which is going to be required to get us there we also have another shot on goal, by the way, an mrnage technology. the only company with two vaccines, two shots on goal. we're delighted to be bringing them forward and trying to do something to help do something right across the world >> testing is also something that everyone thinks in lieu of the 18 months you're talking about for a vaccine, if you knew you already had it, if you knew who did, who didn't, who was susceptible, so there's a startup called luminotics. what you're envisioning is a way for people not to go anywhere near a health care worker or hospital setting but completely able to do something at home, self-administer the test and then -- go into how that wil work you get the results, there's an app on your smartphone what do you envision, paul >> let me take a step back getting back to normal next year is going to be about vaccines, people knowing whether they have the virus or not you know, we did the collaboration on the vaccine three weeks for two large companies and then at the other end of the scale we partnered

have not contracted the virus even though they have been exposed this new development from pfizer mrnasically give a piece of the covid-19 virus into people and they will react to that antigen, to that product that's made become immune even though they never got the virus. the key is to testing to show efficacy. give people the shot, make sure that they will still exposed to the virus as we are today in america. and because we are exposed, if significant number of people aren't vaccined get it and that's different from people vaccinated then have you got good evidence. for the high risk people for emergency use can you begin to use it by the end of the year. i must caution folks, i have had dr. hotez big time vaccine expert dr. lipton a well known epidemiologist. both of them have told me they don't think we will have widespread vaccine available for another year but we might have something by the end of this year. and i'm encouraged by what i'm reading. ainsley: that's good news that would be wonderful. at least if we had it for emergency use this fall. okay. there is a study that say

there are — there is an approach called mrna vaccine that people like moderna, curevac and several othersoach, which unfortunately, the schedule for that probably wouldn't be as quick as this rna programme we've been funding directly and through cepi over the last decade. you'll be aware a lot of people in the uk are asking a simple and straightforward question, which is, when will there be a vaccine? what — how do you see that? well, it's a perfect question, because we want to get back to the life we had before coronavirus. and people are seeing the economic destruction, the psychological stress. you know, this is such an unprecedented, very tough thing to deal with. the — people like myself and tony fauci are saying 18 months. if everything went perfectly, we could do slightly better than that, but there will be a trade—off. we'll have less safety testing than we typically would have, and so, governments will have to decide do they indemnify the companies and say "let's go out with this" when we just don't have the time to do what we normally do. so 18 months is about what we would expe